Harrell Investment Partners LLC Lowers Holdings in AbbVie Inc. $ABBV

Harrell Investment Partners LLC reduced its stake in shares of AbbVie Inc. (NYSE:ABBV) by 6.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 30,427 shares of the company’s stock after selling 2,272 shares during the period. AbbVie accounts for about 1.7% of Harrell Investment Partners LLC’s investment portfolio, making the stock its 15th largest position. Harrell Investment Partners LLC’s holdings in AbbVie were worth $7,045,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently bought and sold shares of the company. Brighton Jones LLC increased its stake in AbbVie by 17.4% during the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after acquiring an additional 3,401 shares during the last quarter. Revolve Wealth Partners LLC increased its position in AbbVie by 72.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock worth $1,294,000 after purchasing an additional 3,064 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new position in AbbVie in the first quarter valued at approximately $383,000. Acadian Asset Management LLC lifted its position in AbbVie by 5.7% during the first quarter. Acadian Asset Management LLC now owns 142,756 shares of the company’s stock valued at $29,898,000 after buying an additional 7,640 shares in the last quarter. Finally, Mattson Financial Services LLC grew its stake in AbbVie by 4.0% during the first quarter. Mattson Financial Services LLC now owns 5,211 shares of the company’s stock worth $1,092,000 after buying an additional 201 shares during the period. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Citigroup reduced their target price on shares of AbbVie from $240.00 to $235.00 and set a “neutral” rating on the stock in a report on Monday, November 3rd. Piper Sandler restated an “overweight” rating and set a $289.00 price objective (up previously from $284.00) on shares of AbbVie in a research note on Wednesday, November 5th. Guggenheim increased their target price on AbbVie from $227.00 to $242.00 and gave the company a “buy” rating in a research note on Monday, October 20th. Cantor Fitzgerald set a $250.00 price target on AbbVie and gave the stock an “overweight” rating in a research report on Thursday, October 9th. Finally, Morgan Stanley increased their price objective on shares of AbbVie from $261.00 to $269.00 and gave the company an “overweight” rating in a research report on Friday, December 12th. Three research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $246.89.

AbbVie Stock Down 3.9%

Shares of ABBV stock opened at $224.22 on Friday. The company has a market cap of $396.28 billion, a P/E ratio of 169.86, a PEG ratio of 0.98 and a beta of 0.36. The business has a 50 day moving average of $226.55 and a two-hundred day moving average of $214.86. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The company had revenue of $15.78 billion for the quarter, compared to analysts’ expectations of $15.58 billion. During the same period last year, the business posted $3.00 earnings per share. The firm’s quarterly revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Analysts expect that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be given a $1.73 dividend. The ex-dividend date is Friday, January 16th. This represents a $6.92 annualized dividend and a yield of 3.1%. This is an increase from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s payout ratio is 496.97%.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Pipeline progress: AbbVie advanced its Phase 2 icalcaprant trial in depression, which keeps a potential late-stage CNS asset on the radar and preserves upside if clinical data are positive. Read More.
• Positive Sentiment: New oncology program: AbbVie launched a first‑in‑human ABBV‑901 ovarian cancer trial, expanding its oncology pipeline and creating a longer-term growth optionality. Read More.
• Positive Sentiment: Real‑world evidence readouts: Post‑marketing/observational studies for Rinvoq (Korea) and upadacitinib (Japan) wrapped up, which can support label, payer conversations and uptake in key markets. Read More. Read More.
• Positive Sentiment: Analyst support and dividend narrative: Berenberg upgraded to a Buy and investor commentary emphasizing AbbVie’s reliable dividend/ income profile may underpin longer‑term demand from income-focused funds. Read More. Read More.
• Neutral Sentiment: Event calendar: AbbVie scheduled its full‑year and Q4 2025 earnings release and call for Feb. 4 — an upcoming catalyst where management can clarify guidance drivers. Read More.
• Negative Sentiment: Guidance nudged below consensus: AbbVie updated Q4 2025 EPS to $3.320–3.360 (vs. street ~3.360) and FY 2025 to $10.610–10.650 (vs. ~10.650), a small miss that removes near‑term upside expectations. (Company guidance release)
• Negative Sentiment: One‑time accounting hit: Management flagged IPR&D and related expenses that will negatively impact Q4 EPS, pressuring reported profitability this quarter. Read More.
• Negative Sentiment: M&A rumor volatility: Reports the company was in talks to buy Revolution Medicines briefly lifted both stocks; AbbVie subsequently denied talks, a reversal that likely contributed to intraday selling pressure. Read More. Read More.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.